CJC-1295
Overview
CJC-1295 is a synthetic 30-amino acid analogue of Growth Hormone Releasing Hormone (GHRH), modified with a Drug Affinity Complex (DAC) to extend its half-life from minutes to approximately 6–8 days by binding to serum albumin. It stimulates pituitary GH release via the GHRH receptor. A Phase I/II clinical pharmacokinetic study (PMID 16352683) used doses of 30–60 mcg/kg in healthy adults. Frequently combined with Ipamorelin in research settings to achieve synergistic amplification of GH pulses. Not approved for therapeutic use outside clinical trials. Consult a licensed physician before use.
Dosage
1000 mcg · Any time · Can take on empty stomach
Key Interactions
1 verified interaction found
CJC-1295 (GHRH analogue) and Ipamorelin (ghrelin receptor agonist) act via distinct but complementary receptor pathways. Research suggests their combination produces amplified GH pulse amplitude compared to either agent alone, as GHRH increases the number of GH-secreting cells while ghrelin mimetics increase GH release per cell.
This combination is frequently studied together in research settings. Both remain unapproved research compounds outside clinical trials. Consult a licensed physician before any use.
View details →What Experts Say
“"I can't see why anyone would specifically select CJC-1295 until all these safety issues have been resolved"”
Huberman explicitly advises against CJC-1295 due to serious safety concerns. A death was reported in clinical trials related to cardiovascular dysfunction. It causes fluid retention and has a very long half-life (days) due to its DAC modification, meaning prolonged uncontrolled exposure. It is still in clinical trials with unresolved safety issues.
“"CJC-1295 with drug affinity complex basically extends the half-life significantly — but these are not FDA approved compounds. These are literally the wild west of compounds."”
Derek (MPMD) explains CJC-1295 to Peter Attia as a GHRH analogue. The DAC version significantly extends half-life (allowing less frequent dosing) and pairs with GHRPs like Ipamorelin to stimulate both arms of the GH axis simultaneously. Derek flags the regulatory status bluntly: CJC-1295 is not FDA approved — "literally the wild west of compounds."
Scientific Sources
Frequently Asked Questions
What is CJC-1295 used for?
CJC-1295 is a synthetic 30-amino acid analogue of Growth Hormone Releasing Hormone (GHRH), modified with a Drug Affinity Complex (DAC) to extend its half-life from minutes to approximately 6–8 days by binding to serum albumin.
What is the recommended dosage for CJC-1295?
1000 mcg. Any time. Can take on empty stomach.
Does CJC-1295 interact with other supplements?
CJC-1295 has 1 verified interactions. Top: Ipamorelin.
When is the best time to take CJC-1295?
Any time. Can take on empty stomach.
Is CJC-1295 safe to combine with other supplements?
Always check interactions before combining supplements. Use VitalStack to verify your full stack for free.
Check how CJC-1295 fits your full stack
Verify interactions, get timing plans, and optimize your supplement routine — free.
Check Your Stack →Not medical advice. VitalStack is not a medical device. For personalized health recommendations, consult a healthcare provider.